Table 6.
Characteristics and outcomes of patients with AE who failed short-term first-line immunotherapy.
| Variable |
No additional treatment group (n = 32) |
Repetition of first-line treatment group (n = 12) |
Second-line treatment group (n = 15) |
P -value |
|---|---|---|---|---|
| Age (year), median (IQR) | 51 (35–65) | 57 (35–67) | 26 (15–49) | 0.007 |
| Sex, female, n (%) | 16 (50) | 3 (25) | 9 (60) | 0.178 |
| BMI (Kg/m2), median (IQR) | 23.49 ± 2.75 | 23.95 ± 2.25 | 21.67 ± 2.75 | 0.052 |
| Median time from symptom onset until treatment, days (IQR) | 23 (12–35) | 20 (6–40) | 23 (10–32) | 0.476 |
| MRS at study entry, median (IQR) | 4 (3–4) | 4.5 (4–5) | 4 (4–5) | 0.151 |
| Maximum mRS, median (IQR) | 4.5 (4–5) | 5 (4–5) | 5 (4–5) | 0.781 |
| MRS after short-term first-line treatment, median (IQR) | 4 (4–5) | 4 (4–5) | 5 (4–5) | 0.325 |
| Antibody titers, n, (%) | ||||
| Weakly positive | 11 (34.4) | 4 (33.3) | 1 (6.7) | 0.103 |
| Positive | 14 (43.8) | 2 (16.7) | 9 (60.0) | 0.078 |
| Strongly positive | 7 (21.9) | 6 (50) | 5 (33.3) | 0.189 |
| Relapsesa, n (%, total n = 48) | 9 (36) | 1 (11.1) | 2 (14.3) | 0.264 |
| Relapsesb, n (%, total n = 38) | 9 (42.9) | 1 (12.5) | 3 (25.0) | 0.242 |
Values are presented as numbers (%), means ± SD, or medians (interquartile range), p < 0.05 was considered statistically significant.
BMI, body mass index; mRS, modified Rankin scale; IQR, Interquartile range.
relapsesa: : clinical relapses in 12 months.
relapsesb: : clinical relapses in 24 months.